4/A: Structure Therapeutics CSO Corrects Stock Option Exercise Price in Amended SEC Filing

Xichen Lin, Chief Scientific Officer of Structure Therapeutics, files an amendment to a previous SEC Form 4 to correct the exercise price of stock options.

Summary

• Xichen Lin, the Chief Scientific Officer of Structure Therapeutics Inc., filed an amended Form 4 with the SEC.
• The amendment corrects the exercise price of stock options granted on March 15, 2024.
• The exercise price is corrected to reflect the fair market value per Ordinary Share, based on the trading price of the Issuer's American Depositary Shares (ADSs).
• The stock option allows Lin to buy 213,486 Ordinary Shares at an exercise price of $11.75.
• 1/4th of the shares subject to the option shall vest March 1, 2025, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
• Each ADS represents three Ordinary Shares of the Issuer.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The correction of the exercise price suggests attention to detail and compliance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock options, common in the biopharmaceutical industry.

Stakeholder Impact

• The correction of the stock option exercise price ensures transparency and fairness for all stakeholders, including shareholders and employees.

Key Dates